JP2019519599A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519599A5
JP2019519599A5 JP2019510577A JP2019510577A JP2019519599A5 JP 2019519599 A5 JP2019519599 A5 JP 2019519599A5 JP 2019510577 A JP2019510577 A JP 2019510577A JP 2019510577 A JP2019510577 A JP 2019510577A JP 2019519599 A5 JP2019519599 A5 JP 2019519599A5
Authority
JP
Japan
Prior art keywords
alkyl
disease
halo
independently
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519599A (ja
JP7003114B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031367 external-priority patent/WO2017193041A1/en
Publication of JP2019519599A publication Critical patent/JP2019519599A/ja
Publication of JP2019519599A5 publication Critical patent/JP2019519599A5/ja
Application granted granted Critical
Publication of JP7003114B2 publication Critical patent/JP7003114B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510577A 2016-05-05 2017-05-05 統合ストレス経路のモジュレーター Expired - Fee Related JP7003114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332280P 2016-05-05 2016-05-05
US62/332,280 2016-05-05
PCT/US2017/031367 WO2017193041A1 (en) 2016-05-05 2017-05-05 Modulators of the integrated stress pathway

Publications (3)

Publication Number Publication Date
JP2019519599A JP2019519599A (ja) 2019-07-11
JP2019519599A5 true JP2019519599A5 (enExample) 2020-06-25
JP7003114B2 JP7003114B2 (ja) 2022-01-20

Family

ID=58710118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510577A Expired - Fee Related JP7003114B2 (ja) 2016-05-05 2017-05-05 統合ストレス経路のモジュレーター

Country Status (12)

Country Link
US (2) US10836725B2 (enExample)
EP (1) EP3452453B1 (enExample)
JP (1) JP7003114B2 (enExample)
CN (1) CN109689628A (enExample)
AR (1) AR108393A1 (enExample)
AU (1) AU2017260374B2 (enExample)
CA (1) CA3023164A1 (enExample)
ES (1) ES2923875T3 (enExample)
MA (1) MA44866A (enExample)
TW (1) TW201808903A (enExample)
UY (1) UY37229A (enExample)
WO (1) WO2017193041A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200054A (es) 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
HUE062446T2 (hu) 2017-09-01 2023-11-28 Denali Therapeutics Inc Vegyületek, készítmények és eljárások
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37958A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
EP3704089B1 (en) * 2017-11-02 2023-07-19 Calico Life Sciences LLC Modulators of the integrated stress pathway
AU2018383675A1 (en) 2017-12-13 2020-07-09 Altos Labs, Inc. Inhibitors of integrated stress response pathway
MX2020013269A (es) 2018-06-05 2021-02-18 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
EP3820843A1 (en) * 2018-07-09 2021-05-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
TWI771621B (zh) * 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
EP3923935A4 (en) 2019-02-13 2022-10-26 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
CN113840597A (zh) * 2019-02-25 2021-12-24 普拉西斯生物技术有限责任公司 整合应激反应通路抑制剂
CA3137212A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
IL287379B2 (en) 2019-04-23 2025-11-01 Evotec Int Gmbh Modulators of the integrated stress response pathway
CN114466654A (zh) 2019-06-12 2022-05-10 普拉西斯生物技术有限责任公司 整合应激反应通路调节剂
EP4096665A1 (en) 2020-01-28 2022-12-07 Evotec International GmbH Modulators of the integrated stress response pathway
CA3165813A1 (en) 2020-03-11 2021-09-16 Holly Victoria Atton Modulators of the integrated stress response pathway
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
MX2023004626A (es) * 2020-10-22 2023-05-23 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
KR20230110509A (ko) 2020-10-22 2023-07-24 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
AU2021363616B2 (en) 2020-10-22 2026-03-26 Evotec International Gmbh Modulators of the integrated stress response pathway

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
WO2005077900A1 (ja) * 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. ビシクロアミド誘導体
KR101302627B1 (ko) * 2005-01-05 2013-09-10 아비에 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
WO2011087758A1 (en) 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
AR084457A1 (es) 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア eIF2α経路の調節因子
US20160318856A1 (en) 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators

Similar Documents

Publication Publication Date Title
JP2019515042A5 (enExample)
JP2019515043A5 (enExample)
JP2019530649A5 (enExample)
RU2018142740A (ru) Модуляторы интегрированного сигнального пути стресса
JP2013525433A5 (enExample)
JP2018515531A5 (enExample)
JP2019508407A5 (enExample)
JP2009534407A5 (enExample)
JP2013533884A5 (enExample)
AU2020355358A1 (en) PROTAC small molecule compound and application thereof
AU2019217320B2 (en) Steroid derivative regulators, method for preparing the same, and uses thereof
JP2021501789A5 (enExample)
JP2009534406A5 (enExample)
WO2015101928A1 (en) Fused thiophene and thiazole derivatives as ror gamma modulators
CA2797663A1 (en) Compounds that modulate intracellular calcium
IL226912A (en) The history of triazole, their preparation and their pharmaceutical preparations
JP2021501790A5 (enExample)
EP3829561A1 (en) Substituted-3h-imidazo[4,5-c]pyridine and 1h pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (enpp1) and stimulator for interferon genes (sting) modulators as cancer immunotherapeutics
CN114729044B (zh) 毒蕈碱型乙酰胆碱m1受体拮抗剂
JP2021501781A5 (enExample)
JP2020525512A (ja) 癌および他の疾患を処置するためのATF4阻害剤としての2−(4−クロロフェノキシ)−N−((1−(2−(4−クロロフェノキシ)エチンアゼチジン(ethynazetidin)−3−イル)メチル)アセトアミド誘導体および関連化合物
JP2013530236A5 (enExample)
HK1253029A1 (zh) 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物
MX2011006343A (es) Tiazoles como ligandos del receptor de cannabinoide.
MX2009009423A (es) Derivados de 3-ciano-4-(4-fenil-piperidin-1-il)-piridin-2-ona.